New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
09:25 EDTELGX, ELGX, ELGX, ARTC, ARTC, ARTC, BAXS, BAXS, BAXS, NVDQ, NVDQ, NVDQ, OXFD, OXFD, OXFD, FLDM, FLDM, FLDM, Q, Q, Q, ATRC, ATRC, ATRCPiper Jaffray's medtech analysts hold an analyst/industry conference call
The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.
Check below for free stories on ELGX;ARTC;BAXS;NVDQ;OXFD;FLDM;Q;ATRC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
11:18 EDTNVDQNovadaq not granted motion to dismiss in LifeCell case, says Piper Jaffray
Subscribe for More Information
11:07 EDTATRCLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
July 25, 2014
08:30 EDTATRCAtriCure posted outstanding Q2 results, says Canaccord
Subscribe for More Information
July 24, 2014
16:33 EDTATRCAtriCure raises FY14 revenue view to $103M-$105M from $101M-$104M
FY14 consensus $102.57M. Consistent with the guidance provided in February, adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $9M-$10M for 2014, of which approximately $3.5M of expense will be related to the Estech transaction. AtriCure expects the Estech transaction to be dilutive to earnings in 2014 and accretive in 2015 and beyond.
16:31 EDTATRCAtriCure reports Q2 EPS (10c), consensus (19c)
Reports Q2 revenue $26.5M, consensus $25.03M.
July 23, 2014
13:36 EDTNVDQIntuitive Surgical rises after Q2 EPS, revenue beat expectations
Subscribe for More Information
July 18, 2014
07:34 EDTBAXSBaxano Surgical says economic analysis of the AxiaLIF accepted for publication
Baxano Surgical announced that the Journal of Managed Care Medicine, a peer-reviewed national publication, has accepted an economic analysis of the AxiaLIF pre-sacral interbody fusion procedure in comparison to transforaminal lumbar interbody fusion, or TLIF. The analysis, conducted by Scott Parker, MD, Director of the Spinal Column Surgical Quality and Outcomes Research Laboratory at Vanderbilt University, and Dr. Matt McGirt, Carolina Neurosurgery and Spine Associates, Adjunct Associate Professor, University of North Carolina, analyzed the bibliography for AxiaLIF and TLIF procedures and assessed relative costs by looking at reoperation rates, complication rates, blood loss and OR time. The study found that AxiaLIF resulted in an approximately $4,500 lower cost per procedure when looking at these procedural parameters.
July 16, 2014
16:08 EDTATRCAtriCure says AtriClip System surpasses 34,000 units sold
AtriCure announced that it has sold more than 34,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide, quickly becoming the top selling device used for eliminating the left atrial appendage.
July 15, 2014
07:18 EDTNVDQNovadaq has strong products, improved sales team, says Stifel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use